MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.

What symbol and exchange does Metavia shares trade?

Metavia trades on the NASDAQ stock market under the symbol MTVA.

What is Metavia stock price doing today?

As of October 30, 2026, MTVA stock price declined to $1.12 with 56,022 million shares trading.

What is Metavia's Beta?

MTVA has a beta of 2.30, meaning it tends to be more sensitive to market movements. MTVA has a correlation of 0.02 to the broad based SPY ETF.

How much is Metavia worth?

MTVA has a market cap of $7.38 million. This is considered a Sub-Micro Cap stock.

What are the top ETFs holding Metavia?

The top ETF exchange traded funds that MTVA belongs to (by Net Assets): VXF.

Is Metavia (MTVA) a good investment?

MTVA has underperformed the market in the last year with a price return of -89.6% while the SPY ETF gained +12.3%. MTVA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.2% and -11.1%, respectively, while the SPY returned +2.1% and -1.0%, respectively.

What are the support and resistance levels for Metavia (MTVA)?

MTVA support price is $1.11 and resistance is $1.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MTVA shares will trade within this expected range on the day.